MedTrace Logo

Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")

NCT01985399 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-10-17

No results posted yet for this study

Summary

Investigators hypothesize that older HIV-infected individuals (i.e., \>50 years old) on efavirenz (EFV)-containing antiretroviral therapy (ART) will have significantly worse neurocognitive function than older individuals on non-EFV-containing ART.

Conditions

Interventions

BEHAVIORAL

Neuropsychological testing

Neuropsychological testing

Sponsors & Collaborators

Principal Investigators

  • Philip Grant, MD · Stanford University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01985399 on ClinicalTrials.gov